Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1999 Sep;43(9):2320-2.
doi: 10.1128/AAC.43.9.2320.

Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents

C Betriu  1 , M Gómez, M L Palau, A Sánchez, J J Picazo
Affiliations
Comparative Study

Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents

C Betriu et al. Antimicrob Agents Chemother. 1999 Sep.

Abstract

The antimicrobial activities of trovafloxacin, moxifloxacin, sanfetrinem, quinupristin-dalfopristin, and 14 other antimicrobial agents against 218 Bacteroides fragilis group strains were determined. A group of 10 imipenem-resistant strains were also tested. Imipenem, meropenem, and sanfetrinem had the lowest MICs of all of the beta-lactams. Quinupristin-dalfopristin inhibited all of the strains at 2 microg/ml. Overall, the MICs of trovafloxacin and moxifloxacin for 90% of the strains tested were 1 and 2 microg/ml, respectively.

PubMed Disclaimer

References

    1. Aldridge K E, Gelfand M, Reller L B, Ayers L W, Pierson C L, Schoenknecht F, Tilton R C, Wilkins J, Henderberg A, Schiro D D, Johnson M, Janney A, Sanders C V. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamycins, penicillins, clindamycin and metronidazole in the United States. Diagn Microbiol Infect Dis. 1994;18:235–241. - PubMed
    1. Aldridge K E, Ashcraft D S. Comparison of the in vitro activities of Bay-128039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother. 1997;41:709–711. - PMC - PubMed
    1. Appelbaum P C, Spangler S K, Jacobs M R. Susceptibility of 539 Gram-positive and Gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam. J Antimicrob Chemother. 1993;32:223–231. - PubMed
    1. Babini G S, Yuan M, Livermore D M. Interactions of β-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral β-lactams. Antimicrob Agents Chemother. 1998;42:1168–1175. - PMC - PubMed
    1. Bandoh K, Ueno K, Watanabe K, Kato N. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: a 4-year study. Clin Infect Dis. 1993;16(Suppl. 4):S382–S386. - PubMed

Publication types